Good morning :)
$
₹
Nexgel Inc

Nexgel Inc

NXGL

NASDAQ
Asset Logo

Nexgel Inc

NXGL

NASDAQ
$420.47% (-1.03)
$
₹
$420.47% (-1.03)
High
—
—
Low
—
—
Returns
—
—
Loading...
1D
1W
1M
3M
6M
1Y
3Y
5Y
Max

Healthcare

Medical Instruments & Supplies

Micro Cap

With a market cap of $2.5M the stock is ranked 6098

Key Metrics

Key Metrics

PE TTM
PE TTM

Close price divided by the earnings per share for the trailing twelve months

—
PB
PB

Close price divided by the book value per share at the end of the most recent quarter

0.49
EPS TTM
EPS TTM

Net profit earned per share over the trailing twelve months (sum of the last 4 quarters)

$-14.8
PEG Ratio
PEG Ratio

Price-to-Earnings (P/E) ratio divided by the forecasted annual earnings per share (EPS) growth rate over the next five years

—
Profit Margin
Profit Margin

Net profit divided by the total revenue for the most recent financial year

-51.26%
Dividend Yield
Dividend Yield

Annual dividend per share for the trailing twelve months divided by the close price

—

Analyst Ratings & Forecast

Analyst Ratings & Forecast

Detailed Forecast Detailed Forecast 

Based on 1 analyst's reports

Buy
0 analyst
Hold
1 analyst
Sell
0 analyst

Price Upside

-60.24%

Earnings Growth

-4389.02%

Rev. Growth

+38.23%

See Detailed Forecast

Company Profile

Company Profile

NEXGEL, Inc. manufactures high water content, electron beam cross-linked, and aqueous polymer hydrogels and gels for wound care, medical diagnostics, transdermal drug delivery, and cosmetics in the United States. It operates through two segments: Nexgel and CG labs. The company offers over-the-counter remedy solutions, such as blister and pain applications; and beauty and cosmetic solutions. It also develops NEXDrape, an incise surgical drape designed for patients with impaired skin; and NEXDerm, an adhesive tape designed to secure central lines and intravenous tubes and devices to patients before, during, and after medical treatment. In addition, the company engages in the converting and packaging business. It serves its customers under Medagel, Kenkoderm and Silly George brand names. The company was formerly known as AquaMed Technologies, Inc. and changed its name to NEXGEL, Inc. in November 2019. NEXGEL, Inc. was incorporated in 2009 and is based in Langhorne, Pennsylvania.
NEXGEL, Inc. manufactures high water content, electron beam cross-linked, and aqueous polymer hydrogels and gels for wound care, medical diagnostics, transdermal drug delivery, and cosmetics in the United States. It operates through two segments: Nexgel and CG labs. The company offers over-the-counter remedy solutions, such as blister and pain applications; and beauty and cosmetic solutions. It also develops NEXDrape, an incise surgical drape designed for patients with impaired skin; and NEXDerm, an adhesive tape designed to secure central lines and intravenous tubes and devices to patients before, during, and after medical treatment. In addition, the company engages in the converting and packaging business. It serves its customers under Medagel, Kenkoderm and Silly George brand names. The company was formerly known as AquaMed Technologies, Inc. and changed its name to NEXGEL, Inc. in November 2019. NEXGEL, Inc. was incorporated in 2009 and is based in Langhorne, Pennsylvania.

Peers

Compare with peers Compare with peers 

Peers

Compare with peers Compare with peers 
Abbott Laboratories
ABT
Abbott Laboratories
P/E Ratio
38.55
38.55
1Y Return
18.86%
18.86%
Buy Reco %
85.71
85.71
Danaher Corporation
DHR
Danaher Corporation
P/E Ratio
38.16
38.16
1Y Return
3.48%
3.48%
Buy Reco %
83.33
83.33
Intuitive Surgical Inc
ISRG
Intuitive Surgical Inc
P/E Ratio
54.69
54.69
1Y Return
17.95%
17.95%
Buy Reco %
76.47
76.47
Medtronic PLC
MDT
Medtronic PLC
P/E Ratio
23.44
23.44
1Y Return
1.27%
1.27%
Buy Reco %
66.66
66.66
Stryker Corporation
SYK
Stryker Corporation
P/E Ratio
31.82
31.82
1Y Return
19.81%
19.81%
Buy Reco %
79.31
79.31
Compare with Peers

Forecast

Forecast

Price

Revenue

Earnings

Price Forecast

Price Forecast

Lower price growth forecast versus trailing 3-year CAGR
Compares analyst forecast growth with historical annualized growth.

The 12-month consensus target implies -60.24% growth, versus a trailing 3-year CAGR of -44.86%.

2026
Current$5.03Baseline
Analyst Target - 1 year
Target$2-60.24%

All values in $

202220232024202520262027$25.88$49.96$74.04Target-60.24%
2026
Current$5.03Baseline
Analyst Target - 1 year
Target$2-60.24%

All values in $

Revenue Forecast

Revenue Forecast

Lower revenue growth forecast versus trailing 3-year CAGR
Compares analyst forecast growth with historical annualized growth.

The next fiscal year's mean estimate implies 38.23% growth, versus a trailing 3-year CAGR of 77.33%.

2025
Current$11.42Baseline
Forecast for Dec 2026
High$15.78+38.23%
Average$15.78+38.23%
Low$15.78+38.23%

All values in $ Million

2021202220232024202520261.552.044.088.6811.42Low+38.23%Average+38.23%High+38.23%
2025
Current$11.42Baseline
Forecast for Dec 2026
High$15.78+38.23%
Average$15.78+38.23%
Low$15.78+38.23%

All values in $ Million

Earnings Per Share Forecast

Earnings Per Share Forecast

2025
Current$-0.42Baseline
Forecast for Dec 2026
High$-18.8-4389.02%
Average$-18.8-4389.02%
Low$-18.8-4389.02%

All values in $

202120222023202420252026-1.01-0.79-0.62-0.51-0.42Low-4389.02%Average-4389.02%High-4389.02%
2025
Current$-0.42Baseline
Forecast for Dec 2026
High$-18.8-4389.02%
Average$-18.8-4389.02%
Low$-18.8-4389.02%

All values in $

Financials

Financials

Income

Balance Sheet

Cash Flow

2.9
-0.6
2.7
-0.9
2.6
-0.9
3.6
-3.6
Q3 2025
Q4 2025
Q1 2026
Q2 2026
Revenue
Net Income
Financial YearQ1 2024Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026
Total Revenue1.261.442.943.042.802.882.932.792.653.68
Net Income-0.85-0.88-0.69-0.85-0.71-0.66-0.65-0.97-0.92-3.63
Net Profit Margin-67.37%-61.45%-23.57%-27.95%-25.37%-23.05%-22.25%-34.69%-34.98%-98.61%
See CostsAll values in $ Million

Peers

Peers & Comparison

Peers & Comparison

Comparing 2 stocks from
HealthcareMedical Instruments & Supplies

Valuation

Returns

Forecast

ScreenerCompare valuation on Screener
StockPE TTMPE TTMPBPBPEG RatioPEG Ratio
Nexgel Inc -0.49-
Abbott Laboratories38.553.572.12
Danaher Corporation38.162.951.32
ScreenerCompare valuation on Screener

Price Comparison

Price Comparison

Compare NXGL with any stock or ETF
Compare NXGL with any stock or ETF
Comparing from
NXGL
ABT
DHR
Loading...

Frequently asked questions

  1. Nexgel Inc (NXGL) share price today is $4.00 as of October 27, 2026 at 12:55 AM IST. The stock touched a day high of $4.49 and a day low of $3.93.

  2. Nexgel Inc stock trades on NASDAQ under the ticker symbol NXGL.

  3. Nexgel Inc's market capitalization is $2.45M as of October 27, 2026 at 12:55 AM IST.

  4. Nexgel Inc's price-to-earnings (P/E) ratio is N/A as of October 26, 2026.

  5. Nexgel Inc's price-to-book (P/B) ratio is 0.49 as of October 26, 2026.

  6. Yes, You can buy Nexgel Inc shares from India through Tickertape, via our partnership with ViewTrade IFSC under the IFSCA Global Access framework, subject to RBI’s Liberalised Remittance Scheme (LRS) limits.

  7. Indian investors can buy Nexgel Inc shares in three steps: 1. Search Nexgel Inc on the Tickertape app and tap Invest. 2. Complete your one-time digital KYC. 3. Fund your account and buy from as low as $1 via fractional shares.

  8. Since Nexgel Inc trades in USD, an Indian investor's INR returns depend on both the stock's price movement and the USD-INR exchange rate. If the rupee depreciates against the dollar, INR returns are boosted beyond the stock's USD return; if the rupee appreciates, INR returns are reduced.

  9. Indian investors can start investing in Nexgel Inc (NXGL) shares from as little as $1 through fractional ownership on Tickertape - for example, $10 buys approximately 2.5 shares at the current price of $4.00.

Loading...